Skip to content
Constant Therapeutics

News & Events

Page 2 of 2
Results: 13

Tarix Orphan, LLC Announces Positive Results with TXA127 in Animal Model of Congenital Muscular Dystrophy

Results Warrant Further Research into TXA127 as a Comprehensive Single Agent Therapeutic for this Genetic Muscle Disease Cambridge, MA (August 3, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead compound, TXA127, has shown positive results in […]

Tarix Orphan, LLC Announces Positive Results with TXA127 in Animal Model of ALS

Noted ALS Researcher, Robert H. Brown, Jr., Ph.D., M.D., Joins Tarix Orphan Strategic Advisory Board Cambridge, MA (July 13, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead compound, TXA127, has shown positive results in the preclinical […]

Tarix Orphan, LLC Announces Positive Results for TXA127 in Model of Limb Girdle Muscular Dystrophy

Cambridge, MA (October 27, 2014): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead product candidate, TXA127, has achieved positive results in an established mouse model of Limb Girdle Muscular Dystrophy. SGCD‐/‐ (sarcoglycan delta deficient) mice demonstrate reduced […]